Malassezia factor with antibiotic activity

Patent metadata

Field	Value
Publication number	US-11820799-B2
Application number	US-202217827244-A
Country	US
Kind code	B2
Filing date	May 27, 2022
Priority date	May 28, 2021
Publication date	Nov 21, 2023
Grant date	Nov 21, 2023

Abstract

Compositions including an antibiotic factor from Malassezia are provided. In some examples, the compositions include a Malassezia exoproduct, a Malassezia cell-free supernatant, or a Malassezia cell and a pharmaceutically acceptable carrier. Methods of treating an infection in a subject, such as a Staphylococcus infection are also provided.

First claim

We claim:

1. A method of inhibiting bacterial growth, infection, and/or skin colonization in a subject, comprising administering to the subject a composition comprising:
a Malassezia exoproduct, a Malassezia cell-free supernatant, or a Malassezia cell; and
a pharmaceutically acceptable carrier.

2. The method of claim 1 , wherein the bacteria is a Staphylococcus species.

3. The method of claim 2 , wherein the Staphylococcus species is S. aureus , methicillin-resistant S. aureus (MRSA), vancomycin-resistant S. aureus (VRSA), S. epidermidis, S. haemolyticus , or S. warneri.

4. The method of claim 1 , wherein the composition is administered orally or intravenously.

5. The method of claim 1 , wherein the composition is administered topically.

6. The method of claim 1 , further comprising administering to the subject an additional antibiotic therapy.

7. The method of claim 6 , wherein the additional antibiotic therapy is administered to the subject prior to, concurrently with, or following treatment with the composition.

8. The method of claim 1 , wherein the Malassezia is Malassezia sympodialis, Malassezia restricta , or Malassezia globosa.

9. The method of claim 2 , wherein the method inhibits growth of the Staphylococcus by at least 10-fold compared to a control.

10. The method of claim 1 , wherein the Malassezia exoproduct exhibits one or more of heat resistance, binding to non-polar molecules, and pH sensitivity.

11. The method of claim 10 , wherein the pH sensitivity comprises antimicrobial activity at pH of about 6 or less.

12. The method of claim 1 , wherein the composition comprises about 0.01%-10% w/w, 0.01-10% v/v, or 0.01-10% w/v of the Malassezia exoproduct, cell free supernatant, or cells.

13. The method of claim 1 , wherein the composition further comprises an additional antibiotic compound.

14. The method of claim 5 , wherein the composition is formulated as a solution, a gel, an ointment, a cream, or a suspension.

15. The method of claim 1 , wherein the pharmaceutically acceptable carrier is a base comprising a plurality of inactive ingredients.

Assignees

• Univ Oregon

Inventors

• Barber Matthew
• Kowalski Caitlin

Classifications

• C07K14/37 Primary

  from fungi · CPC title

• A61P31/04 Primary

  Antibacterial agents · CPC title

• A61K38/00

  Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00) · CPC title

• C12N1/14

  Fungi (culture of mushrooms A01G18/00; as new plants A01H15/00); Culture media therefor · CPC title

• C12P1/02

  by using fungi · CPC title